


We claim:

1. A compound of formula I

5



(I)

and pharmaceutically acceptable salts and solvates thereof,
10 characterized in that the compound is in particulate form,
said particles having a mean particle size of less than
about 25 microns.

2. The compound of Claim 1 wherein said
15 particles have a mean particle size of between about 5 and
about 20 microns.

3. The compound of Claim 2 wherein at least
about 90% of said particles have a size of less than about
20 50 microns.

4. The compound of Claim 3 wherein at least
90% of said particles have a size of less than about 35
microns.

25 5. A compound of Claim 1 which is the non-
solvated crystalline 6-hydroxy-2-(4-hydroxy-phenyl)-3-[4-
(2-piperidinoethoxy)benzoyl]benzo[b]thiophene hydrochloride

BEST AVAILABLE COPY

having substantially the following X-ray diffraction pattern obtained with copper radiation:

	d-line spacing (Angstroms)	I/I ₀ (x100)
5	13.3864	71.31
	9.3598	33.16
	8.4625	2.08
	7.3888	7.57
	6.9907	5.80
	6.6346	51.04
	6.1717	29.57
	5.9975	5.67
	5.9135	9.87
	5.6467	38.47
10	5.4773	10.54
	5.2994	4.74
	4.8680	4.03
	4.7910	5.98
	4.6614	57.50
	4.5052	5.75
15	4.3701	9.03
	4.2516	69.99
	4.2059	57.64
	4.1740	65.07
	4.0819	12.44
	3.9673	22.53
20	3.9318	100.00
	3.8775	9.07
	3.7096	33.38
	3.6561	21.65
	3.5576	3.36
	3.5037	7.97
25	3.4522	18.02
	3.4138	4.65
	3.2738	10.23
	3.1857	8.90

3.1333	6.24
3.0831	9.43
3.0025	12.13
2.9437	4.96
2.8642	7.70
2.7904	11.95
2.7246	3.05
2.6652	3.32
2.5882	7.30

10

6. A pharmaceutical formulation comprising or formulated using the compound of Claim 5 and one or more pharmaceutically acceptable carriers, diluents, or excipients.

15

7. A pharmaceutical composition comprising or formulated using a compound according to Claim 1, or a pharmaceutically acceptable salt or solvate thereof, in combination with one or more pharmaceutically acceptable carriers, diluents or excipients.

20

8. A method of inhibiting osteoporosis comprising administering an effective amount of a compound of formula I to a person in need thereof.

25

9. A method of lowering serum lipid levels comprising administering a compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, to a person in need thereof.

30

10. A method for preventing breast cancer comprising administering to a woman in need thereof an effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof.

35


11. An article of manufacture comprising packaging material containing a pharmaceutical formulation,

said packaging material further containing labeling indicating said pharmaceutical formulation is useful for inhibiting a human pathology, said pharmaceutical formulation comprising or formulated using a compound of

5

Claim 1.

12. A compound of formula I



10

(I)

and pharmaceutically acceptable salts and solvates thereof, characterized in that the compound is in particulate form, at least about 90% of said particles having a particle size of less than about 50 microns.

15

20

13. The compound of Claim 12 wherein at least about 90% of said particles have a size of less than 35 microns.

14. The compound of Claim 13 wherein said particles have a mean particle size of less than about 25 microns.

25

15. The compound of Claim 14 wherein said particles have a mean particles size of between about 5 and about 20 microns.

16. A compound of Claim 12 which is the non-solvated crystalline 6-hydroxy-2-(4-hydroxy-phenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene hydrochloride, having substantially the following X-ray diffraction pattern obtained with copper radiation:

	d-line spacing (Angstroms)	I/I ₀ (x100)
	13.3864	71.31
10	9.3598	33.16
	8.4625	2.08
	7.3888	7.57
	6.9907	5.80
	6.6346	51.04
15	6.1717	29.57
	5.9975	5.67
	5.9135	9.87
	5.6467	38.47
	5.4773	10.54
20	5.2994	4.74
	4.8680	4.03
	4.7910	5.98
	4.6614	57.50
	4.5052	5.75
25	4.3701	9.03
	4.2516	69.99
	4.2059	57.64
	4.1740	65.07
	4.0819	12.44
30	3.9673	22.53
	3.9318	100.00
	3.8775	9.07
	3.7096	33.38
	3.6561	21.65
35	3.5576	3.36
	3.5037	7.97
	3.4522	18.02

	3.4138	4.65
	3.2738	10.23
	3.1857	8.90
	3.1333	6.24
5	3.0831	9.43
	3.0025	12.13
	2.9437	4.96
	2.8642	7.70
	2.7904	11.95
10	2.7246	3.05
	2.6652	3.32
	2.5882	7.30

17. A pharmaceutical formulation comprising or
15 formulated using the compound of Claim 16, and one or more
pharmaceutically acceptable carriers, diluents, or
excipients.

18. A pharmaceutical composition comprising or
20 formulated using a compound according to Claim 12, or a
pharmaceutically acceptable salt or solvate thereof, with
one or more pharmaceutically acceptable carriers, diluents
or excipients.

25 19. A method of inhibiting osteoporosis
comprising administering to a person in need thereof an
effective amount of a compound of claim 12, or a
pharmaceutically acceptable salt or solvate thereof.

30 20. A method of lowering serum lipid levels,
comprising administering to a person in need thereof an
effective amount of a compound of Claim 12, or a
pharmaceutically acceptable salt or solvate thereof.


effective amount of a compound of Claim 12, or a pharmaceutically acceptable salt or solvate thereof.

22. An article of manufacture comprising packaging material containing a pharmaceutical

5 formulation, said packaging material further containing labelling indicating said pharmaceutical formulation is useful for inhibiting a human pathology, said pharmaceutical formulation comprising or formulated using a compound of Claim 12.

10

23. A compound of formula I



(I)

15 and pharmaceutically acceptable salts and solvates thereof, characterized in that the compound is in particulate form, said particles having a mean particle size of between about 20 5 and about 20 microns, at least about 90% of said particles having a size of less than about 35 microns.

24. A compound according to Claim 23 wherein it 25 is the hydrochloride salt thereof.

25. A compound of Claim 23 which is the non-solvated crystalline 6-hydroxy-2-(4-hydroxy-phenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b] thiophene

hydrochloride, having substantially the following x-ray diffraction pattern obtained with copper radiation:

	d-line spacing (Angstroms)	I/I ₀ (x100)
5	13.3864	71.31
	9.3598	33.16
	8.4625	2.08
	7.3888	7.57
	6.9907	5.80
	6.6346	51.04
	6.1717	29.57
	5.9975	5.67
	5.9135	9.87
	5.6467	38.47
10	5.4773	10.54
	5.2994	4.74
	4.8680	4.03
	4.7910	5.98
	4.6614	57.50
	4.5052	5.75
	4.3701	9.03
	4.2516	69.99
	4.2059	57.64
	4.1740	65.07
15	4.0819	12.44
	3.9673	22.53
	3.9318	100.00
	3.8775	9.07
	3.7096	33.38
	3.6561	21.65
	3.5576	3.36
	3.5037	7.97
	3.4522	18.02
	3.4138	4.65
20	3.2738	10.23
	3.1857	8.90

	3.1333	6.24
	3.0831	9.43
	3.0025	12.13
	2.9437	4.96
5	2.8642	7.70
	2.7904	11.95
	2.7246	3.05
	2.6652	3.32
	2.5882	7.30
10		
	26. A pharmaceutical formulation comprising or formulated using the compound of Claim 25 and one or more pharmaceutically-acceptable carriers, diluents, or excipients.	
15		
	27. A pharmaceutical composition comprising or formulated using a compound according to Claim 23, or a pharmaceutically acceptable salt or solvate thereof, with one or more pharmaceutically acceptable carriers, diluents or excipients.	
20		
	28. A method for inhibiting osteoporosis comprising administering to a person in need thereof an effective amount of a compound of Claim 23, or a pharmaceutically acceptable salt or solvate thereof.	
25		
	29. A method of lowering serum lipid levels, comprising administering an effective amount of a compound of Claim 23, or a pharmaceutically acceptable salt or solvate thereof, to a person in need thereof.	
30		
	30. A method for preventing breast cancer comprising administering to a woman in need thereof an effective amount of a compound of Claim 23, or a pharmaceutically acceptable salt or solvate thereof.	

31. An article of manufacture comprising
packaging material containing a pharmaceutical formulation,
said packaging material further containing labeling
indicating said pharmaceutical formulation is useful for
5 inhibiting a human pathology, said pharmaceutical
formulation comprising or formulated using a compound of
Claim 23.